Easton Pharmaceuticals, Inc. (OTCMKTS:EAPH) Picks Up Even Stronger
The new week turned positive again for pot stocks, though the gains remain comparatively subdued. Easton Pharmaceuticals, Inc. (OTCMKTS:EAPH) added more than 57% to stand at $0.0243, on buying volumes above $1.32 million. The last three days show another marked trend, though let’s not forget that EAPH is just rearing its head into the price range of a few cents, after a long spell as a sub-penny selection. 
EAPH is running up on momentum for now, perhaps an expectation of further news, but so far, the stem cell and medical cannabis company has not been propped up by either PR or a new email. And the negotiations of partnerships on medical marijuana are at best vague, as of the last piece of news stating that EAPH would be testing the Canadian market. 
While waiting for a boost, investors’ forums are immensely optimistic that for EAPH, the last few days are just the beginning of an even larger breakout, though with warnings that there may not be all that long-term potential, and the ticker is an opportunity for trading and not so much for holding. EAPH is still far from releasing a treatment, and its stem cell activities so far yield almost no results.
Still, in the past month EAPH rounded off a 100% growth, which may add to the impression and the momentum. Like other small cap cannabis stocks, EAPH slid a few days ago, for a while shaving off about 25% of its price, but the recovery was even faster. In terms of financials, EAPH is mostly typical of penny stock companies with high promises but thin padding:
- cash: $95 thousand
- total current assets: $208 thousand
- total current liabilities: $406 thousand
- revenues: $0
- net loss: $47 thousand
At a much higher position, Fusion Pharm, Inc. (OTCMKTS:FSPM) is handling the peak well, but for now drifts sideways around the $3 level. Almost no price is a guarantee against stalling, and for the pot stocks around, while the general trend is upward, there are weaker days that may test the patience.
AVT, Inc. (OTCMKTS:AVTC) and its tenuous relation to medical marijuana mean for now that the company had its days of wild gains, touched $5 but later went on to slide a bit, currently treading water a bit below $4. It is unknown if AVTC attracts enough interest for another run, but among pot stocks, fame engenders more fame, and less popular selections fall by the wayside.
If you like the pharmaceutical side of the cannabis boom, it is best not to rely too much on the companies’ promise, as the development and release of drugs may take time, and that would be outrun by the movement in the stock price. In the case of EAPH, at such a low price it is best to protect yourself from volatility by only investing sums you can afford to lose.
